頻尿・尿失禁に対する塩酸テロジリンの臨床評価

Abstract

Detrusor instabilityに基づく頻尿・尿失禁患者99例(うち安全性のみ対象例3例を含む)を対象に, 塩酸テロジリン1日24 mg, 4週間経口投与した.1)最終全般改善率は88.5%であった.2)自覚症状の改善率は昼間頻尿66.2%, 夜間頻尿68.0%, 尿失禁68.8%, 夜間遺尿78.3%であった.3)投与前後の平均1日排尿回数は昼間で14.0回から9.8回へ, 夜間で4.1回から2.6回へ, 平均尿失禁回数は4.4回から1.1回へと有意に減少した.4)残尿10 ml未満と残尿10 ml以上100 ml未満の2群間において, 症状別改善率に有意差を認めず, 両群ともに良好な成績が得られた.5)副作用は10例にみられたが, うち8例は口渇であり重篤なものはなかった.6)有用性は88.5%であった

A clinical trial with the collaboration of 15 department of urology was performed to determine the usefulness of terodiline hydrochloride in 99 patients whose chief complaints were of pollakisuria or incontinence due to neurogenic bladder, psychogenic disease or chronic cystitis. The patients were orally given 24 mg once daily for 4 weeks. The final global improvement rate was 88.5% and the effective rates on subjective symptoms were; 66.2% for diurnal urinary frequency, 68.0% for nocturnal urinary frequency, 68.8% for urinary incontinence and 78.3% for nocturnal enuresis. Even for the cases having mild bladder outlet obstructive disease, the clinical effective rates were good. Mild side effects were observed in 10 patients, which were dry mouth and others. The results obtained from this trial suggest that terodiline hydrochloride may be useful for the treatment of urinary frequency and incontinence caused by detrusor instability.